Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?

Published in: Journal of cell communication and signaling (2019)

mTOR, the target of rapamycin, has been promoted as a potential target for cancers, transplantations and even lung fibrosis. However, paradoxically, targeting mTOR has been reported to result in profibrotic side effects. Some recent publications highlight why this might be.

Keyphrases

cell proliferation
cancer therapy
young adults
drug delivery
risk assessment
drug induced